NO329588B1 - Anvendelse av benzazepin-N-eddiksyrederivater til fremstilling av farmasoytiske preparater for behandling av sekundaeformer av hypertensjon - Google Patents
Anvendelse av benzazepin-N-eddiksyrederivater til fremstilling av farmasoytiske preparater for behandling av sekundaeformer av hypertensjon Download PDFInfo
- Publication number
- NO329588B1 NO329588B1 NO20013958A NO20013958A NO329588B1 NO 329588 B1 NO329588 B1 NO 329588B1 NO 20013958 A NO20013958 A NO 20013958A NO 20013958 A NO20013958 A NO 20013958A NO 329588 B1 NO329588 B1 NO 329588B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- alkyl
- forms
- phenyl
- hypertension
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title claims description 35
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 9
- NTQSYIWTDXTRGG-UHFFFAOYSA-N 2-(1-benzazepin-1-yl)acetic acid Chemical class OC(=O)CN1C=CC=CC2=CC=CC=C12 NTQSYIWTDXTRGG-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 27
- 150000002148 esters Chemical class 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- -1 dioxolanylmethyl group Chemical group 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 150000007513 acids Chemical class 0.000 claims description 10
- 208000019622 heart disease Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 201000004239 Secondary hypertension Diseases 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 230000001146 hypoxic effect Effects 0.000 description 12
- 210000001147 pulmonary artery Anatomy 0.000 description 11
- 230000002685 pulmonary effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 230000004872 arterial blood pressure Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 210000005242 cardiac chamber Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 208000032594 Vascular Remodeling Diseases 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001991 dicarboxylic acids Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 210000005241 right ventricle Anatomy 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002236 anti-hypertrophic effect Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- QJJDBWAEIBNZPQ-UHFFFAOYSA-N 2-(3h-1,2-benzothiazepin-2-yl)acetic acid Chemical class S1N(CC(=O)O)CC=CC2=CC=CC=C21 QJJDBWAEIBNZPQ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- SYAKTDIEAPMBAL-UHFFFAOYSA-N aminorex Chemical compound O1C(N)=NCC1C1=CC=CC=C1 SYAKTDIEAPMBAL-UHFFFAOYSA-N 0.000 description 1
- 229950002544 aminorex Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- HZZGDPLAJHVHSP-GKHTVLBPSA-N big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906310A DE19906310A1 (de) | 1999-02-16 | 1999-02-16 | Arzneimittel zur Behandlung von Bluthochdruck |
| PCT/EP2000/001068 WO2000048601A1 (de) | 1999-02-16 | 2000-02-10 | Arzneimittel zur behandlung von bluthochdruck |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20013958D0 NO20013958D0 (no) | 2001-08-15 |
| NO20013958L NO20013958L (no) | 2001-10-15 |
| NO329588B1 true NO329588B1 (no) | 2010-11-15 |
Family
ID=7897580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013958A NO329588B1 (no) | 1999-02-16 | 2001-08-15 | Anvendelse av benzazepin-N-eddiksyrederivater til fremstilling av farmasoytiske preparater for behandling av sekundaeformer av hypertensjon |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6482820B2 (cs) |
| EP (1) | EP1154777B1 (cs) |
| JP (1) | JP2002537258A (cs) |
| KR (2) | KR20010101922A (cs) |
| CN (1) | CN1198619C (cs) |
| AR (1) | AR036864A1 (cs) |
| AT (1) | ATE295174T1 (cs) |
| AU (1) | AU773240C (cs) |
| BR (1) | BR0008260A (cs) |
| CA (1) | CA2362273C (cs) |
| CZ (1) | CZ301499B6 (cs) |
| DE (2) | DE19906310A1 (cs) |
| DZ (1) | DZ3014A1 (cs) |
| ES (1) | ES2238268T3 (cs) |
| HK (1) | HK1042247B (cs) |
| HU (1) | HUP0105491A3 (cs) |
| IL (1) | IL144622A (cs) |
| NO (1) | NO329588B1 (cs) |
| NZ (1) | NZ514058A (cs) |
| PL (1) | PL195283B1 (cs) |
| PT (1) | PT1154777E (cs) |
| RU (1) | RU2270679C2 (cs) |
| SK (1) | SK287254B6 (cs) |
| TR (1) | TR200102386T2 (cs) |
| TW (1) | TWI221770B (cs) |
| UA (1) | UA63032C2 (cs) |
| WO (1) | WO2000048601A1 (cs) |
| ZA (1) | ZA200105828B (cs) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| ES2310527T3 (es) * | 1999-11-19 | 2009-01-16 | Solvay Pharmaceuticals B.V. | Enzimas humanas de la familia de las metaloproteasas. |
| ATE367815T1 (de) * | 2000-10-04 | 2007-08-15 | Astellas Pharma Inc | Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension |
| BR0209855A (pt) * | 2001-05-18 | 2004-06-15 | Solvay Pharm Gmbh | Uso de compostos com atividade inibidora de nep/mp combinada na preparação de medicamentos |
| AP1758A (en) * | 2001-09-10 | 2007-07-30 | Tibotec Pharm Ltd | Method for the preparation of hexahydro-furo [2,3-b]furan-3-ol. |
| BR0306701A (pt) * | 2002-01-16 | 2004-12-28 | Solvay Pharm Bv | Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal |
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| WO2004062692A1 (en) * | 2003-01-13 | 2004-07-29 | Solvay Pharmaceuticals B.V. | Formulation of poorly water-soluble active substances |
| US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| SA04250283B1 (ar) * | 2003-09-26 | 2008-05-26 | سولفاي فارماسيتيكالز جي أم بي أتش | مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid |
| CN100566719C (zh) | 2003-11-18 | 2009-12-09 | 索尔瓦药物有限公司 | 用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物 |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
| US20050288272A1 (en) * | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| RU2410118C2 (ru) | 2004-12-15 | 2011-01-27 | Зольвай Фармасьютиклз Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ |
| US20060205625A1 (en) * | 2005-02-18 | 2006-09-14 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics |
| US20070292503A1 (en) * | 2006-06-16 | 2007-12-20 | Gorissen Henricus R | Oral pharmaceutical composition of poorly water-soluble active substance |
| US20070299054A1 (en) * | 2006-06-22 | 2007-12-27 | Rajesh Jain | Oral pharmaceutical composition of a poorly water-soluble active agent |
| PT2247297T (pt) * | 2008-01-31 | 2019-04-24 | Univ Vanderbilt | Tratamento terapêutico para estados pulmonares |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| US4749688A (en) * | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| CA1337400C (en) * | 1987-06-08 | 1995-10-24 | Norma G. Delaney | Inhibitors of neutral endopeptidase |
| US5087702A (en) * | 1991-01-30 | 1992-02-11 | Merck & Co., Inc. | Microbial transformation process for producing an antihypertensive product |
| US5362727A (en) * | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
| DE19510566A1 (de) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
-
1999
- 1999-02-16 DE DE19906310A patent/DE19906310A1/de not_active Ceased
-
2000
- 2000-01-20 AR ARP000100257A patent/AR036864A1/es unknown
- 2000-01-21 TW TW089101041A patent/TWI221770B/zh not_active IP Right Cessation
- 2000-02-10 AU AU25476/00A patent/AU773240C/en not_active Ceased
- 2000-02-10 CZ CZ20012672A patent/CZ301499B6/cs not_active IP Right Cessation
- 2000-02-10 RU RU2001124604/15A patent/RU2270679C2/ru not_active IP Right Cessation
- 2000-02-10 HU HU0105491A patent/HUP0105491A3/hu unknown
- 2000-02-10 TR TR2001/02386T patent/TR200102386T2/xx unknown
- 2000-02-10 PT PT00903681T patent/PT1154777E/pt unknown
- 2000-02-10 ES ES00903681T patent/ES2238268T3/es not_active Expired - Lifetime
- 2000-02-10 CA CA2362273A patent/CA2362273C/en not_active Expired - Fee Related
- 2000-02-10 NZ NZ514058A patent/NZ514058A/en not_active IP Right Cessation
- 2000-02-10 EP EP00903681A patent/EP1154777B1/de not_active Expired - Lifetime
- 2000-02-10 PL PL00350167A patent/PL195283B1/pl not_active IP Right Cessation
- 2000-02-10 JP JP2000599393A patent/JP2002537258A/ja active Pending
- 2000-02-10 AT AT00903681T patent/ATE295174T1/de active
- 2000-02-10 WO PCT/EP2000/001068 patent/WO2000048601A1/de not_active Application Discontinuation
- 2000-02-10 KR KR1020017009705A patent/KR20010101922A/ko not_active Ceased
- 2000-02-10 KR KR1020077001387A patent/KR100797665B1/ko not_active Expired - Fee Related
- 2000-02-10 SK SK1082-2001A patent/SK287254B6/sk not_active IP Right Cessation
- 2000-02-10 DE DE50010284T patent/DE50010284D1/de not_active Expired - Lifetime
- 2000-02-10 BR BR0008260-0A patent/BR0008260A/pt not_active Application Discontinuation
- 2000-02-10 HK HK02104121.2A patent/HK1042247B/zh not_active IP Right Cessation
- 2000-02-10 CN CNB008038236A patent/CN1198619C/zh not_active Expired - Fee Related
- 2000-02-13 DZ DZ000029A patent/DZ3014A1/xx active
- 2000-10-02 UA UA2001096336A patent/UA63032C2/uk unknown
-
2001
- 2001-07-16 ZA ZA200105828A patent/ZA200105828B/en unknown
- 2001-07-30 IL IL144622A patent/IL144622A/en not_active IP Right Cessation
- 2001-08-15 NO NO20013958A patent/NO329588B1/no not_active IP Right Cessation
- 2001-08-16 US US09/930,186 patent/US6482820B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329588B1 (no) | Anvendelse av benzazepin-N-eddiksyrederivater til fremstilling av farmasoytiske preparater for behandling av sekundaeformer av hypertensjon | |
| PH27176A (en) | Pharmaceutical compositions containing dipyridamole or mopidamole and O-acetylsalicyclic acid or the physiologically acceptable salts thereof | |
| EP1909757A2 (en) | Oral liquid losartan compositions | |
| JP2002537258A5 (cs) | ||
| JPWO2006118212A1 (ja) | 膵炎の予防および治療剤 | |
| DK164638B (da) | Kombinationspraeparat af pyrimido-pyrimidiner og acetylsalicylsyre og/eller deres farmaceutisk acceptable salte, fremgangsmaade til dets fremstilling samt anvendelse af pyrimido-pyrimidiner og acetylsalicylsyre og/eller salte deraf sammen med farmaceutiske baerere til fremstilling af et kombinationspraeparat | |
| US5840741A (en) | Arteriosclerosis depressant | |
| KR20010107927A (ko) | 면역 조절용 약학 조성물 | |
| CN101460197A (zh) | 有机化合物的组合 | |
| WO1994005290A1 (en) | Platelet aggregation inhibitor | |
| EP1687006B1 (en) | Pharmaceutical compositions for the treatment of renal dysfunction | |
| RU2084225C1 (ru) | Гипотензивное средство | |
| HK175896A (en) | Medicament for the treatment of cardiac insufficiency | |
| AU602867B2 (en) | Prostacyclines, their analogues or prostaglandines and thromboxane antagonists for the treatment of thrombotic and thrombo-embolic illnesses | |
| CA1297100C (en) | Medicament for curing arteriosclerosis, comprising pyrimido [2,1-b]-benxothiazole derivative | |
| US3821381A (en) | Method of treatment | |
| US4788200A (en) | Method and composition for treating arteriosclerosis | |
| MXPA01008164A (en) | Medicament for treating hypertension | |
| CN120093885A (zh) | 用于治疗高血压继发心力衰竭的药物组合物 | |
| JPH1192377A (ja) | 免疫調節用医薬組成物 | |
| WO2021108303A1 (en) | Pharmaceutical compositions for the treatment of pulmonary hypertension | |
| WO2017072636A1 (en) | Pharmaceutical synergistic combination | |
| JPH0393720A (ja) | 腸の運動過剰症の治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |